
Jun Hatazawa, Kiichi Ishiwata, Masatoshi Itoh, Motonobu Kameyama, Kazuo Kubota, Tatsuo Ido, Taiju Matsuzawa, Takashi Yoshimoto, Shoichi Watanuki, and Shinya Seo

Division of Nuclear Medicine, Division of Radiopharmaceutical Chemistry, Cyclotron and Radioisotope Center, Department of Neurosurgery, Tohoku University, School of Medicine, Department of Radiology and Nuclear Medicine, Research Institute for Tuberculosis and Cancer, Tohoku University

Tumor uptake of L-[methyl-\(^{11}\text{C}\)]methionine (\(^{11}\text{C}\)Met) was assessed in six patients with brain tumors and three patients with lung cancer using positron emission tomography (PET). In arterial plasma samples taken at 5, 15, 30, and 60 min after injection, a fraction of \(^{11}\text{C}\)Met was measured using high performance liquid chromatography in individual patients. Employing curve fitting, a history of \(^{11}\text{C}\)Met activity was obtained as an input function. By means of sequential PET scannings and graphic analysis, uptake rate and distribution volume of \(^{11}\text{C}\)Met in tumor tissue were calculated. In two studies irreversible uptake into the tumors was not seen when total plasma \(^{11}\text{C}\) activity was used as the input; however when \(^{11}\text{C}\)Met plasma activity was used, definite irreversible uptake was seen, indicating tumor viability. In other studies, up to 24% underestimation of uptake rate was found. The present results demonstrated the importance of measuring \(^{11}\text{C}\)Met in plasma for quantitative assessment of in vivo amino acid metabolism in tumors.


Positron emission tomography (PET) using L-[methyl-\(^{11}\text{C}\)]methionine (\(^{11}\text{C}\)Met) as a tracer has been used to measure in vivo amino acid metabolism in human brain (1–3), brain tumors (3–7), and lung cancer (8–10).

Although accurate measurement of plasma radioactivity of an injected labeled amino acid, apart from its metabolites, is essential for accurate compartmental analysis, we have found no reports including such measurements in individual studies. We previously measured the metabolic products of \(^{11}\text{C}\)Met in human plasma during PET-methionine study and found remarkable individual differences in the clearance pattern of plasma \(^{11}\text{C}\)Met (11). Herein, we evaluate the uptake rate and distribution volume of \(^{11}\text{C}\)Met in brain tumors and lung cancer using graphic analysis (12) after correction for plasma metabolites of \(^{11}\text{C}\)Met in individual cases. The importance of plasma metabolite analysis for quantitative assessment is demonstrated.

MATERIALS AND METHODS

Patients

Six patients with brain tumors and three patients with lung cancer were studied with positron emission tomography (PET) and \(^{11}\text{C}\)Met between November 1987 and December 1988. Clinical information is summarized in Table 1. All the patients with brain tumors had partial resection of tumors or stereotaxic biopsy. One patient with lung cancer (ID 590) was studied twice during radio- and chemotherapy. Each patient fasted prior to the study. The dose of whole-body radiation was 12 mrad/mCi of \(^{11}\text{C}\)Met in an adult man with a body weight of 70 kg (13). Informed consent was obtained from the patients or the parents (ID 714). The present project was approved by the Committee for Clinical PET Study of Tohoku University.

Scanner and Procedure

ECAT II (EG&G, Ortec) (14) and PT-931 (CTI, Knoxville, TN) (15) were employed. The spacial resolution of the image...
were centrifuged for 3 mm. The precipitate was resuspended in cold 0.2 M HClO₄ to precipitate plasma proteins. The samples and 60 min after i.v. injection were treated with 5 ml of ice-cold citrate. The column was reequilibrated and the elution profile was obtained with the procedure described above were combined as a protein-bound fraction. Radioactivity of this fraction was then measured. The supernatant was applied to an Aminex A-6 column. The column was eluted with 0.2 N sodium citrate. The column was reequilibrated and the elution profile.

was 15 mm and 8 mm for the ECAT II and PT-931, respectively, and slice thickness was 18 and 9 mm at FWHM, respectively. Three to four images were obtained with the ECAT II at 1 cm center-to-center spacing and 14 images were obtained with PT-931 at 8 mm spacing. The sequential scan was performed for one of these slices where the tumor was most visible in x-ray CT or MRI.

Before scanning, a short 21-gauge cannula was inserted to a brachial or radial artery for arterial blood sampling. Fourteen to 24 mCi of [¹¹C]Met were administered within 30 sec through the contralateral hand vein. Repeated scanning started just after administration. Eight to ten sequential images with 5-min data acquisition were obtained. During the scanning, 1-ml arterial blood samples were taken at 0.33, 0.67, 1, 1.5, 2.0, 2.5, 3.0, 4.0, 5.0, 7.5, 10, 15, 20, 30, 40, 50, 60 min after the i.v. administration and at the end of scanning. These blood samples were centrifuged for 3 min, and plasma samples were weighed and counted for radioactivities using a cross-calibrated well counter with ECAT II and PT-931. At 5, 15, 30, and 60 min, additional 3-ml arterial blood samples were obtained for analysis of protein-bound [¹¹C] and [¹¹C]Met in plasma using high performance liquid chromatography (HPLC).

Analysis of Metabolites of [¹¹C]Met in Plasma

Protein-bound and protein-free metabolites of [¹¹C]Met in plasma were analyzed under the same conditions as described previously (11). Briefly, after counting total radioactivity, plasma samples taken at 3, 4, 5, 7.5, 10, 15, 20, 30, 40, 50, and 60 min after i.v. injection were treated with 5 ml of ice-cold 0.2 M HClO₄ to precipitate plasma proteins. The samples were centrifuged for 3 min. The precipitate was resuspended in 5 ml of 0.2 M HClO₄, and centrifuged again. This washing procedure was repeated twice. The final precipitate, counted for radioactivity and corrected for decay, was considered to be the protein-bound fraction.

For the samples taken at 5, 15, 30, and 60 min, supernatants obtained with the procedure described above were combined as a protein-free fraction. Radioactivity of this fraction was then measured. The supernatant was applied to an Aminex A-6 column. The column was eluted with 0.2 N sodium citrate. The column was reequilibrated and the elution profile was measured with a radioactivity monitor (Ramona-D equipped with an IM-2020X flow cell, Raytest). The collected effluent in 1.0 ml fraction was then counted for radioactivity with a well counter.

Uptake Rate and Distribution Volume of [¹¹C]Met

We obtained three different input functions of [¹¹C] radioactivity for each study, total [¹¹C] radioactivity, protein-free [¹¹C] (total minus protein-bound fraction) and radioactivity for [¹¹C]Met. For total [¹¹C] in plasma, integrated radioactivity from injection time to midway in each sequential scanning was calculated using a BLD computer program (16). For protein-free [¹¹C] and [¹¹C]Met, plasma radioactivity against sampling time was fitted best to double exponential curves using the Damped Gauss Newton method.

A small fraction of serin was found in the HPLC analysis. This fraction was not considered as an input because the brain uptake index of serin is almost one-fourth of that of methionine (17).

As only a low percentage of protein-free metabolites and an undetectable amount of protein-bound metabolites were found in the samples taken at 5 min after administration, total radioactivity before 5 min was incorporated as a protein-free fraction and [¹¹C]Met fraction for curve fitting. The integrated radioactivity from injection time to the midtime of scanning and the radioactivity at the midpoint were obtained using these fitted curves.

The PET images were reconstructed using a measured attenuation correction, and radioactivity concentration in each pixel was converted to nCi/ml unit. Oval regions of interest were located on brain tumors and brain matter in the contralateral hemisphere in the sequential images. For lung tumors, regions of interest were superimposed on the tumor masses which were visible in the transmission images.

Plasma and tissue time-activity curves were treated with graphic analysis which enables evaluation of the unidirectional transfer process (12). The operational equation is

\[
\frac{C_i(T)}{C_o(T)} = K_i \int_{0}^{T} \frac{C_p(t)dt}{C_o(T)} + V_s
\]

where \(C_i(T)\) is the total amount of [¹¹C] radioactivity at time \(T\).
in the tissue, $K_i$ is the rate constant for tracer transfer from the blood to the tissue of interest, $C_p(T)$ is the tracer concentration in blood at time $T$, and $V_o$ is the distribution volume of tracer. When a linear portion of the curve was identified, the slope ($K_o$) and the intercept ($V_o$) were calculated.

**RESULTS**

Table 2 shows the ratios of protein-free $^{11}$C and $[^{11}C]$Met to total $^{11}$C at 15, 30 and 60 min in each study. The mean radioactivity ratio of plasma $[^{11}C]$Met to total $^{11}$C was 0.89 (s.d. = 0.09) at 15 min, 0.67 (s.d. = 0.19) at 30 min and 0.36 (s.d. = 0.17) at 60 min after administration. There were marked individual differences in the clearance rate of plasma $[^{11}C]$Met.

Tissue distribution of the tracer injected in a patient with a brain tumor (ID 619) and in another patient with lung cancer (ID 552) is shown in Figure 1. Besides the initial distribution of $[^{11}C]$Met in large vessels, accumulations in tumor tissue were visualized in both cases.

Figure 2 illustrates the graphic analysis of brain tumors and lung cancer for total $^{11}$C and $[^{11}C]$Met in plasma as an input function. The slopes for total $^{11}$C and $[^{11}C]$Met were visually identical in four patients (ID 552, 606, 333 and 758). In two studies (ID 590-1, 590-2), it was difficult to find a linear part in the plots without metabolite correction. In four cases (ID 600, 619, 629, and 714), there was a discrepancy of the slopes obtained with and without such correction. Table 3 shows uptake rates and distribution volumes for $[^{11}C]$Met in plasma as an input. In one case of lung cancer (ID 590), the values were calculated only after metabolite correction.

Mean uptake rate (min$^{-1}$) and distribution volume (ml/ml tissue) in the contralateral brain matter before metabolite correction was 0.019 (s.d. = 0.006) and 0.41 (s.d. = 0.16), respectively. After metabolite correction,

**TABLE 2**

<table>
<thead>
<tr>
<th>ID</th>
<th>15 min</th>
<th>30 min</th>
<th>60 min</th>
<th>15 min</th>
<th>30 min</th>
<th>60 min</th>
</tr>
</thead>
<tbody>
<tr>
<td>552</td>
<td>0.99</td>
<td>0.83</td>
<td>0.43</td>
<td>0.93</td>
<td>0.70</td>
<td>0.29</td>
</tr>
<tr>
<td>590</td>
<td>0.75</td>
<td>0.31</td>
<td>0.26</td>
<td>0.67</td>
<td>0.21</td>
<td>0.09</td>
</tr>
<tr>
<td>590</td>
<td>0.91</td>
<td>0.54</td>
<td>0.26</td>
<td>0.80</td>
<td>0.44</td>
<td>0.16</td>
</tr>
<tr>
<td>600</td>
<td>0.95</td>
<td>0.83</td>
<td>0.67</td>
<td>0.93</td>
<td>0.72</td>
<td>0.48</td>
</tr>
<tr>
<td>606</td>
<td>1.00</td>
<td>0.87</td>
<td>0.43</td>
<td>0.96</td>
<td>0.74</td>
<td>0.24</td>
</tr>
<tr>
<td>619</td>
<td>1.00</td>
<td>0.81</td>
<td>0.54</td>
<td>0.85</td>
<td>0.65</td>
<td>0.34</td>
</tr>
<tr>
<td>629</td>
<td>1.00</td>
<td>0.93</td>
<td>0.63</td>
<td>0.91</td>
<td>0.75</td>
<td>0.33</td>
</tr>
<tr>
<td>714</td>
<td>1.00</td>
<td>0.99</td>
<td>0.66</td>
<td>0.92</td>
<td>0.85</td>
<td>0.42</td>
</tr>
<tr>
<td>333</td>
<td>1.00</td>
<td>0.98</td>
<td>0.87</td>
<td>0.97</td>
<td>0.89</td>
<td>0.72</td>
</tr>
<tr>
<td>758</td>
<td>1.00</td>
<td>0.94</td>
<td>0.65</td>
<td>0.96</td>
<td>0.78</td>
<td>0.49</td>
</tr>
<tr>
<td>Mean</td>
<td>0.96</td>
<td>0.80</td>
<td>0.54</td>
<td>0.89</td>
<td>0.67</td>
<td>0.36</td>
</tr>
<tr>
<td>s.d.</td>
<td>0.08</td>
<td>0.20</td>
<td>0.18</td>
<td>0.09</td>
<td>0.19</td>
<td>0.17</td>
</tr>
</tbody>
</table>

**FIGURE 1**

Sequential images of brain tumor (ID 619, 1A) and lung cancer (ID 552, 1B) are shown from the top left to the bottom right in order of scanning. In both studies, increased radioactivities in the tumor indicated by an arrow were observed. However, it is difficult to evaluate $[^{11}C]$Met incorporated in protein synthesis. In 1B, transmission image of the chest is also shown. A; anterior, P; posterior, R; right, L; left.
mean uptake rate and distribution volume changed to 0.022 (s.d. = 0.008) and 0.36 (s.d. = 0.09), respectively.

DISCUSSION

As realized by Lundqvist et al. (18) and Ishiwata et al. (11), the fraction of [11C]Met in plasma decreased significantly after venous administration. Carbon-11 activity was detected in the protein fraction and in the protein-free fraction (methionine, serine, and unknown origin). Therefore, when the total amount of [11C] activity in plasma is employed as an input function, serious error in measurement of physiologic parameters might be anticipated.

Bergstrom et al. (6) estimated methionine accumulation in glioma and normal brain tissue using graphic analysis. In their study, plasma radioactivity was corrected mathematically for labeled plasma proteins by subtracting a fraction according to Lundqvist et al. (18). However, as reported here, there was large variation in the clearance pattern of [11C]Met among individuals. Another group (7) evaluated the slope and intercept of the initial straight line of the plot after administering [11C]Met to avoid the presence of plasma metabolites in the late phase of the study. However, an irreversible fraction of total radioactivities in the tumor or [11C] Met incorporated into protein might increase during scanning. For example, Ishiwata et al. reported that only 42% of radioactivity in rat tumor was incorporated into proteins at 5 min after [11C]Met injection and then the percentage increased to 72.4% at 30 min and 76.8% at 60 min (19). Therefore, more reliable values for incorporated [11C]Met could be obtained by measuring tissue radioactivities as long as possible.

When protein-free [11C] radioactivity was employed as an input function, the magnitude of error was much smaller than that obtained for total 11C. However, values still ranged from 0.3% to 12% with a mean difference of 6%. This might suggest that protein-free 11C, which was much easier to measure than [11C]Met with HPLC, could not be substituted for [11C]Met as input when accurate measurements are requested.

We previously reported that 11C activity in the tumor corrected for administered dose and body weight, a differential uptake ratio (DUR), was an indicator of tumor viability (8). The uptake rate obtained in this study was significantly correlated with DUR value (p < 0.05). However, DUR included no information regarding the fraction of incorporated [11C]Met. Tumor viability should be evaluated by an irreversible fraction of [11C]Met incorporated into amino acid.

In conclusion, because of considerable variations in

![Figure 2](image_url)

**FIGURE 2**
Graphic analysis of all the patients obtained for [11C]MET (●) and total 11C (○) as an input. Abscissa: normalized time (min) ordinate: Ci(t)/ Cp(t).
clearance patterns of administered $[^{14}\text{C}]$Met, the corrections for plasma metabolites should be performed to obtain $[^{14}\text{C}]$Met plasma radioactivity as an input when quantitative information regarding methionine metabolism is extracted in the PET study.

REFERENCES


Jun Hatazawa, Kiichi Ishiwata, Masatoshi Itoh, Motonobu Kameyama, Kazuo Kubota, Tatsuo Ido, Taiju Matsuzawa, Takashi Yoshimoto, Shoichi Watanuki and Shinya Seo


This article and updated information are available at:
http://jnm.snmjournals.org/content/30/11/1809

Information about reproducing figures, tables, or other portions of this article can be found online at:
http://jnm.snmjournals.org/site/misc/permission.xhtml

Information about subscriptions to JNM can be found at:
http://jnm.snmjournals.org/site/subscriptions/online.xhtml